Hyperoxaluria: all 51 studies

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07776626Phase 1
• Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07587021Phase 2
• Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing the Relationship Between Oxalate Levels and Vitamin C Levels in PlasmaNot yet recruitingNCT06578754
• Gut Oxalate Absorption in Calcium Oxalate Stone DiseaseRecruitingNCT06331546Not applicable
• O. Formigenes Colonization in Calcium Oxalate Kidney Stone DiseaseRecruitingNCT06330246Not applicable
• Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone PatientsNot yet recruitingNCT05443932Phase 4
• Gut Kidney Axis in Enteric HyperoxaluriaRecruitingNCT05124886Not applicable
• Monogenic Kidney Stone - Genetic TestingRecruitingNCT03305835
• Prospective Research Rare Kidney Stones (ProRKS)RecruitingNCT02780297
• Rare Kidney Stone Consortium BiobankRecruitingNCT02026388
• Rare Kidney Stone Consortium Patient RegistryRecruitingNCT00588562
• A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.CompletedNCT06481150Phase 4Results posted
• A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedNCT04152200Phase 3Results posted
• A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedNCT03905694Phase 3Results posted
• An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1CompletedNCT03350451Phase 2Results posted
• A Pilot Study of Oxalate Absorption in Secondary HyperoxaluriaCompletedNCT03095885Not applicableResults posted
• Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With HyperoxaluriaCompletedNCT02289755Phase 2Results posted
• Hydroxyproline Influence on Oxalate MetabolismCompletedNCT02038543Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on DialysisCompletedNCT02000219Phase 2Results posted
• Oxazyme in Patients With HyperoxaluriaCompletedNCT01127087Phase 1/2Results posted
• Use of Oral Probiotics to Reduce Urinary Oxalate ExcretionCompletedNCT00587041Phase 1/2Results posted
• Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary HyperoxaluriaCompletedNCT00283387Phase 2Results posted
• Oxalate Excretion Profile in Patients With a Heterozygous Mutation of the AGXT (Alanine-glyoxylate Aminotransferase) GeneCompletedNCT06283082Not applicable
• A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And HyperoxaluriaWithdrawnNCT06138327Phase 1
• Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel SyndromeCompletedNCT05377112Early Phase 1
• Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult SubjectsTerminatedNCT04909723Phase 1/2
• Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in ChildrenCompletedNCT04756024
• Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric HyperoxaluriaCompletedNCT04629170Phase 1
• Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary OxalateCompletedNCT04571359
• Effect of Oxalate and Urate Metabolism on CKD EvolutionStatus unknownNCT04399915
• Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Approved for marketingNCT04125472
• Plasma Oxalate in Patient With Short BowelCompletedNCT04119765
• Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric HyperoxaluriaTerminatedNCT03847090Phase 3
• Evaluate ALLN-177 in Patients With Enteric HyperoxaluriaCompletedNCT03456830Phase 3
• Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and NephrolithiasisCompletedNCT03346369Phase 3
• A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)TerminatedNCT02795325Phase 1
• Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 DaysCompletedNCT02547805Phase 2
• Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney StonesCompletedNCT02503345Phase 2
• Effect of Over-the-counter Dietary Supplements on Kidney Stone RiskCompletedNCT02404701Not applicable
• Primary Hyperoxaluria Mutation Genotyping/PhenotypingCompletedNCT02340689
• Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary HyperoxaluriaCompletedNCT02012985Phase 1/2
• Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter FormigenesCompletedNCT01300039
• Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphateCompletedNCT01281878Phase 2
• Phase 2/3 Oxabact StudyCompletedNCT01037231Phase 2/3
• International Registry for Primary HyperoxaluriaWithdrawnNCT00875823
• Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria PatientsCompletedNCT00638703Phase 2/3
• Primary Hyperoxaluria Mutation GenotypingCompletedNCT00589225
• Enteric Oxalate Absorption Study in Unclassified HyperoxaluriaCompletedNCT00588120Phase 1
• The Effects of Cranberry Juice on Bacterial AdhesionCompletedNCT00318253Not applicable
• Renal Protective Effect of ACEI and ARB in Primary HyperoxaluriaWithdrawnNCT00280215Phase 3
• Proteomic Study of Urinary Stone DiseaseCompletedNCT00199459

← Hyperoxaluria overview